What we got wrong
Corrections
When a published fact turns out to be wrong, we fix the page, move its date and list the fix here. Prices that simply changed are not listed — those are updates, not errors. Spot one we missed? Tell us.
- October 2026IGF-1 LR3: what the evidence shows
Two references listed the wrong authors. The animal studies are by Hill et al. (1999) and Dunshea et al. (2002); the titles, years and PubMed links were already right.
- October 2026SS-31 (elamipretide): what the evidence shows
The MMPOWER-3 trial reference now names its first author, Karaa A, as PubMed lists it.
- October 2026NMN vs NAD+
One reference title was misquoted: the 2026 Nutrients paper is a systematic review and meta-analysis of supplementation “in Adults,” not “in Humans.” Another title had been respelled; it now reads exactly as published. The same respelling was fixed on the NAD+ and Ozempic hands articles.
- October 2026Is compounded tirzepatide still legal?
FDA’s discretion period for 503A semaglutide compounding ended April 24, 2025, not April 22 — FDA’s page says “April 22 … or the court’s decision, whichever is later.” Corrected here and in the compounded semaglutide explainer.
- October 2026Breeze Meds review
Two dates for letters about its pharmacies were wrong; the review now gives the dates printed on the letters themselves.
- October 2026Pallas Health review
Removed a press-mention claim that does not appear on Pallas Health’s own public pages.
- October 2026Tirzepatide, semaglutide and weight-loss injection lists; tirzepatide and semaglutide guides
These pages said compounded tirzepatide and semaglutide can be sold only while the brand-name drug is in shortage. FDA resolved both shortages (Zepbound in late 2024, Wegovy in February 2025); the pages now say so.
Both articles said Oak sells with no subscription. Oak’s own pages now price both drugs as 12-month-plan rates and call its plans a subscription; the articles say that instead.
- August 2026Clover Meds review
We published $96 a month (semaglutide) and $128 (tirzepatide) as month-to-month prices. Those are Clover Meds’ 12-month rates; a single month is $144 and $233.
- August 2026Provider lists
Nine prices quoted per 4, 8 or 12 weeks were being sorted as if they were monthly. Each is now converted to a monthly figure before sorting.
- August 2026PepScribe review
PepScribe wrote in, and it was right: it does publish a price for each compound, its coverage page lists all 50 states, and its monthly price includes shipping. The review had said otherwise on all three.
- August 2026Bodybuilding Health+ review
Three errors: its homepage FAQ does name four pharmacies, it does claim all 50 states (its Terms say otherwise, and the review now shows both), and a plan-price comparison had its arithmetic backwards.
- August 2026CoreAge Rx review
We said CoreAge’s price rises with the dose. Its own FAQ says every dose costs the same; the review and the lists now say flat pricing.
- August 2026Enhance MD review
Its state list has 41 entries, but one is Washington, DC — so it serves 40 states plus DC, and ten states are missing, not nine.
- August 2026Momentum Health 360 review
A regulatory finding was described as one issue when the source lists three; the review now describes all three.
How corrections are handled is set out in the editorial policy.